trial

Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis

NCTId NCT01720095
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 22 (actual)
Sponsored by Nova Scotia Health Authority
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2009-10
Primary completion
2014-12
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Niaspan

Sponsors

Nova Scotia Health AuthorityLead Sponsor

Investigators

1
Heather I Milliken, MDPrincipal Investigator

Sites

1 total
Halifax, Canada

Linked catalysts

1
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis — primary completion2014-12

Facts & assertions

4 sourced
Enrollment
22
Phase
PHASE3
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Niaspan
drug
lead_sponsor
Nova Scotia Health Authority
company
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Heather I Milliken, MD
person